Previous Article | Next Article 
Molecular and Cellular Biology, March 1999, p. 1961-1972, Vol. 19, No. 3
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Neu Differentiation Factor Stimulates
Phosphorylation and Activation of the Sp1 Transcription
Factor
Iris
Alroy,
Lior
Soussan,
Rony
Seger, and
Yosef
Yarden*
Department of Biological Regulation, The
Weizmann Institute of Science, Rehovot 76100, Israel
Received 29 July 1998/Returned for modification 14 September
1998/Accepted 30 November 1998
 |
ABSTRACT |
Neu differentiation factors (NDFs), or neuregulins, are epidermal
growth factor-like growth factors which bind to two tyrosine kinase
receptors, ErbB-3 and ErbB-4. The transcription of several genes is
regulated by neuregulins, including genes encoding specific subunits of
the acetylcholine receptor at the neuromuscular junction. Here, we have
examined the promoter of the acetylcholine receptor
subunit and
delineated a minimal CA-rich sequence which mediates transcriptional
activation by NDF (NDF-response element [NRE]). Using gel mobility
shift analysis with an NRE oligonucleotide, we detected two complexes
that are induced by treatment with neuregulin and other growth factors
and identified Sp1, a constitutively expressed zinc finger
phosphoprotein, as a component of one of these complexes. Phosphatase
treatment, two-dimensional gel electrophoresis, and an in-gel kinase
assay indicated that Sp1 is phosphorylated by a 60-kDa kinase in
response to NDF-induced signals. Moreover, Sp1 seems to act downstream
of all members of the ErbB family and thus may funnel the signaling of
the ErbB network into the nucleus.
 |
INTRODUCTION |
Protein phosphorylation plays an
important role in the transfer of the signal from the cell surface into
the nucleus (27). Several pathways of signal transduction
have been described, including intracellular hormone receptors which
are themselves transcription factors; direct interaction between cell
surface receptors and transcription factors which, upon modification,
translocate to the nucleus; and linear cascades of protein kinases,
e.g., the mitogen-activated protein kinases (MAPKs) (reviewed in
reference 55), that serve as the link between cell
surface receptors and nuclear transcription factors. One of the
best-characterized families of surface receptors that stimulate
transcription through MAPKs is the ErbB family, which consists of four
receptors, ErbB-1 [epidermal growth factor receptor (EGFR)], ErbB-2,
ErbB-3, and ErbB-4. Upon ligand binding, these receptors form different
combinations of homo- and heterodimers, thereby increasing the
diversification potential of signaling and tightly tuning MAPK
activation (51). Each ErbB protein consists of a large
extracellular ligand-binding domain, a single transmembrane segment,
and an intracellular portion containing a tyrosine kinase subdomain and
a carboxy-terminal tail region. Multiple ligands exist for ErbB-1,
ErbB-3, and ErbB-4, which appear to induce distinct homo- and
heterodimers of ErbB proteins. The ligands for ErbB-3 and ErbB-4, Neu
differentiation factors (NDFs) or neuregulins, are peptide growth
factors which bind to and activate their cognate receptors.
The biological activity of neuregulins, inferred from the phenotypes of
knockout mice and cell lines grown in culture (reviewed in reference
11), depicts a role in epithelial cell-mesenchyme and other types of inductive cell-cell interactions. Different isoforms
of neuregulins, also called NDF, heregulin, or the acetylcholine receptor (AChR)-inducing activity, were isolated as activities which
lead to ErbB-2 tyrosine phosphorylation (26, 48, 65) or to
induction of AChR in the neuromuscular synapse (19),
respectively. Only later was it established that the isoforms of the
neuregulin family of ligands do not bind directly to ErbB-2 but
interact with both ErbB-3 and ErbB-4 (58, 62). In situ
hybridization analyses indicated that NDF is expressed predominantly in
parenchymal organs and in the embryonic central and peripheral nervous
systems, in adult brain, and at nerve-muscle synapses (12, 32, 44, 46). Thus, these observations led to the notion that neuregulins control inductive processes through transcriptional regulation of
ligands and receptors involved in heterophilic cell-cell interactions (reviewed in reference 6). However, to date only a
few genes have been shown to be transcriptionally regulated by NDF: the AChR
,
, and
subunits genes were demonstrated to be induced two- to threefold by NDF in muscle cells at the nerve-muscle junction both in vivo and in vitro (3, 12, 32, 60). The AChR genes are selectively expressed in muscle fiber nuclei lying beneath the
synapse, and NDF is currently a leading candidate to be the motor
neuron-derived inducer of AChR expression. Another neuregulin-regulated gene, Krox-20, is a zinc finger transcription factor that is involved in the control of Schwann cell myelination (61). NDF, which regulates the survival and proliferation of rat Schwann cell precursors (17), has been implicated in the induction of Krox-20
expression in Schwann cells during embryogenesis (45).
Another gene known to be regulated by signals generated by NDF binding
to its receptor is the neurotrophin 3 (NT-3) gene, which encodes a Trk
ligand produced by nonneuronal cells immediately surrounding
sympathetic ganglia (64).
The Sp1 family of transcription factors includes three members in
addition to Sp1 itself: the ubiquitously expressed Sp2 and Sp3
(24, 37), and Sp4, whose expression is limited to the brain
(24). Sp1 is a phosphoprotein containing three zinc finger motifs of the Cys-2-His-2 type, which binds with high affinity to GC-
or GT-rich promoter elements (29, 30, 53). Several regions
of the protein are involved in its functional regulation, including
three transactivation domains (14), a DNA binding region,
and a carboxy-terminal domain involved in multimerization and
cooperative transactivation (22, 47). Sp1 has been
demonstrated to act downstream of signaling cascades originating at the
cell surface, and its DNA binding, transcriptional activity, and
protein-protein interactions are regulated by both phosphorylation and
dephosphorylation events (4, 15, 31, 39, 53, 68, 69).
Phosphorylation of Sp1 by casein kinase II results in down-regulation
of its DNA binding and thus in attenuation of transcription of two
genes encoding the D-site binding protein (4, 39) and the
glucose-mediated acetyl coenzyme A carboxylase (68).
Similarly, induction of the
2(I) collagen gene by the transforming
growth factor
involves dephosphorylation of Sp1 (23). In
contrast, Sp1 phosphorylation by protein kinase A (PKA) has been
demonstrated to augment both its DNA binding and transcriptional
activities in HL-60 cells (53). Furthermore, Sp1 is involved
in cell cycle regulation, since its activity is modulated by the
retinoblastoma protein (36), possibly via direct
protein-protein interactions with a member of the retinoblastoma
family, p107 (16). Thus, Sp1 is subjected to multiple
cell-type-specific modes of regulation, which serve in mediating its
role in cell growth and differentiation.
In this study, we show that transcriptional control of NDF target genes
is mediated through Sp1 binding to a CA-rich element shared by the
respective promoters. Binding of NDF, as well as other EGF-like
ligands, to ErbB receptors induces phosphorylation of Sp1 by a putative
60-kDa protein kinase. Subsequently, an Sp1-containing complex is
formed on the CA-rich site (which we call the NDF response element
[NRE]), and this leads to an increase in transcriptional activity.
Apparently, formation of the Sp1-DNA complex at the NRE is not due to
modulation of DNA-binding activity per se, and it probably involves
higher-order protein-protein interactions.
 |
MATERIALS AND METHODS |
Materials and antibodies.
EGF was purchased from Sigma (St.
Louis, Mo.), and recombinant NDF preparations (EGF-like domains) were
from Amgen (Thousand Oaks, Calif.). Radioactive materials were from
Amersham (Little Chalfont, United Kingdom). Rabbit and goat anti-Sp1
polyclonal antibodies were purchased from Santa Cruz Biotechnologies.
The Sp1 antibody is directed toward amino acids 436 to 454 of Sp1. There is no cross-reactivity with other Sp family members. All other
materials were from Sigma, unless otherwise indicated. pCI-Sp1 was the
kind gift of Scott L. Friedman (Mount Sinai Medical Center, New York,
N.Y.).
Plasmids.
The rat AChR
subunit gene promoter fragment
(
228 to +27) was cloned as a BamHI-HindIII
fragment from the p
-228/CAT plasmid (18) into the
BglII-HindIII sites of pSEAP-basic (Clontech
Laboratories, Inc.). To construct p(NRE)3E1b-LUC, a
double-stranded NRE oligonucleotide (top strand,
5'-TCGACTGCCACCCCCACCCCCACATCACC-3') was phosphorylated with
T4 kinase and then cloned into the XhoI site of pE1b-LUC (1). The annealed oligonucleotide was designed to carry a
SalI site at the 5' end and an XhoI site at the
3' end. Automated dideoxynucleotide sequencing established that the
phagemid contained three copies of the NRE oligonucleotide, all in the
same orientation. pGEX-Sp1, a plasmid directing bacterial expression of
a fusion between Sp1 and gluthatione S-transferase (GST),
was constructed by cloning an EcoRI (this end was filled in
with Klenow enzyme)-SmaI fragment from pCI-Sp1 into the
EcoRI (blunt ended by Klenow enzyme) site of pGEX-3X (Pharmacia).
Cell transfection and reporter gene assays.
P-19
teratocarcinoma cells were transfected by the calcium phosphate
precipitation method. The cells were seeded 24 h prior to
transfection at 2 × 105 cells/60-mm dish in growth
medium (alpha minimal essential medium [MEM] supplemented with 10%
fetal calf serum [FCS]) and refed with Dulbecco MEM plus 10% FCS
3 h before transfection. The cells were transfected in triplicate
with 8 µg of reporter plasmid [p
-228/SEAP or
p(NRE)3E1b-LUC] and 2 µg of pCMV-
Gal as an internal
control for transfection efficiency. They were kept in transfection
medium for 14 to 16 h and then washed and refed with growth
medium. At 10 h later, the cells were treated with NDF
(100 ng/ml) in growth medium, or left untreated for 12 h, and then
harvested for luciferase or
-galactosidase assays. Alternatively, an
aliquot of the growth medium was removed and assayed for placental
alkaline phosphatase activity. Secreted alkaline phosphatase (SEAP)
activity was assayed as described by the manufacturer (Clontech
Laboratories, Inc.). In short, 12 h after ligand addition, an
aliquot (110 µl) of the medium was removed and centrifuged to remove
cell debris. The resulting supernatant was mixed (1:3) with SEAP
dilution buffer and incubated for 30 min at 65°C. Assay buffer and
chemiluminescent substrate were added, and the mixture was incubated
for 20 minutes at room temperature. SEAP activity was measured in a
tube luminometer (Turner). Luciferase and
-galactosidase assays were
performed from cells that were scraped in phosphate-buffered saline and divided between two tubes. For the
-galactosidase assay, cells were
centrifuged and resuspended in 50 µl of 0.25 M Tris-HCl (pH 7.5) and
extracts were prepared by six freeze-thaw cycles. The cellular debris
were removed by centrifugation, and an aliquot of the supernatant was
assayed for
-galactosidase activity in sodium phosphate buffer (pH
7.5) containing 1 mM MgCl2, 45 mM
-mercaptoethanol, and
0.88 µg of ONPG
(o-nitrophenyl-
-D-galactopyranoside) per ml.
Extracts for luciferase assays were prepared by resuspending the cells
in 30 µl of lysis buffer (Promega). Following a 10-min incubation at
room temperature, the cellular debris were removed and an aliquot of
the resulting supernatant was mixed with 100 µl of luciferin buffer
(0.1 M Tris-acetic acid, 10 mM magnesium acetate, 1 mM EDTA [pH 8.0],
74 mM luciferin, 2.2 mM ATP). The light intensity was measured with a
luminometer. To exclude variation due to differences in transfection
efficiency, the activities of the reporters luciferase and SEAP were
normalized to the levels of the internal
-galactosidase control at
each point.
Preparation of extracts from whole cells and nuclei.
Whole-cell extracts were prepared from cultures grown in 10-cm dishes.
Cell monolayers were washed twice and scraped in 1 ml of
phosphate-buffered saline containing 2 mM sodium orthovanadate, 10 mM
sodium fluoride, 0.5 µg of leupeptin per ml, 2 µg of aprotinin per
ml, 0.5 µg of pepstatin A per ml, and 0.5 mM benzamidine and transferred to microcentrifuge tubes. After a 10-s centrifugation at
12,000 × g, the cells were resuspended in 0.3 ml of
buffer A (10 mM HEPES-KOH [pH 7.9], 1.5 mM MgCl2, 10 mM
KCl, 0.5 mM dithiothreitol [DTT], 0.2 mM phenylmethylsulfonyl
fluoride [PMSF], 20 mM
-glycerophosphate, 10 mM
p-nitrophenyl phosphate, 400 nM okadaic acid), incubated on
ice for 10 min, vortexed for 10 s, and centrifuged for 10 s as above. The crude cellular extract was resuspended in 30 µl of
buffer C (20 mM HEPES-KOH [pH 7.9], 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA [pH 8.0], 0.5 mM DTT, 0.2 mM PMSF,
20 mM
-glycerophosphate, 10 mM p-nitrophenyl phosphate,
400 nM okadaic acid) incubated on ice for 20 min, and centrifuged
(14,000 × g for 2 min) at 4°C. The protein
concentration was determined by using the Bradford reagent (Bio-Rad
Laboratories). Aliquots (5 µl) of whole-cell extracts were snap
frozen in liquid nitrogen and stored at
70°C. Nuclear extracts were
prepared from cell cultures grown in 150-mm dishes. The cell monolayers
were washed twice with an ice-cold wash buffer (2.7 mM KCl, 1.5 mM
KH2PO4, 136 mM NaCl, 8.1 mM
Na2HPO4 · 7H2O) and once
with buffer A-NE (10 mM Tris-HCl [pH 7.8], 15 mM KCl, 2 mM
MgCl2, 1 mM DTT, 0.1 mM EDTA, 0.2 mM PMSF, 2 µg of
leupeptin per ml, 0.1 mg of aprotinin per ml, 30 mM
-glycerophosphate, 400 nM okadaic acid, 2 mM sodium orthovanadate).
The cells were scraped into 2 ml of buffer A-NE and centrifuged. The
cell pellets were lysed in 1 ml of buffer B (buffer A-NE containing
0.2% Nonidet P-40), pipetted vigorously 10 times, and immediately
centrifuged at 14,000 × g for 2 min to pellet the nuclei. A
concentrated (10×) cytoplasm extraction buffer (0.3 M HEPES-KOH [pH
7.9], 1.4 M KCl, 0.03 M MgCl2) was added to the
supernatant, the mixture was centrifuged for 10 min at
100,000 × g, and the resulting cytoplasmic extract was
snap frozen in liquid nitrogen. The pelleted nuclei were resuspended in
315 µl of buffer C-NE (50 mM Tris-HCl [pH 7.8], 50 mM KCl, 0.1 mM
EDTA, 1 mM DTT, 0.1 M PMSF, 10% glycerol, 30 mM
-glycerophosphate, 400 nM okadaic acid, 2 mM sodium orthovanadate), 35 µl of 3 M ammonium sulfate (pH 7.9) was added, and the mixture was inverted gently for 30 min at 4°C. Following a 15-minute centrifugation step
(200,000 × g at 4°C), an equal volume of 3 M
ammonium sulfate was added to the supernatant, and nuclear proteins
were pelleted at 100,000 × g for 10 min. The pelleted
proteins were resuspended in 50 µl of buffer C-NE for an in-gel
kinase assay and snap frozen in liquid nitrogen. Alternatively,
resuspension was performed in a mixture (1:4) of sample buffer I (0.3%
sodium dodecyl sulfate [SDS], 200 mM DTT, 28 mM Tris-HCl [pH 7.0],
22 mM Tris base) and sample buffer II (9.9 M urea, 4% Nonidet P-40,
2.2% ampholytes, 100 mM DTT) for two-dimensional gel electrophoresis.
Protein concentrations were determined with the Bradford reagent.
Electrophoretic mobility shift assay (EMSA).
Whole-cell
extracts (5 to 10 µg) prepared from untreated cells or cells treated
for the indicated time intervals with NDF or EGF (each at 100 ng/ml)
were incubated for 20 min (at room temperature) with 0.1 ng (20,000 cpm) of double-stranded, end-labeled NRE oligonucleotide probe. The
incubation mixture also contained 250 ng of sheared salmon sperm DNA
per ml and binding buffer (10 mM Tris-HCl [pH 7.5], 25 mM NaCl, 0.5 mM EDTA, 0.1 mg of bovine serum albumin per ml [BSA], 5 mM DTT, 10%
glycerol). Protein-DNA complexes were resolved by electrophoresis on
4% nondenaturing acrylamide gels as described previously
(51). For control of extract activity and quantity, sister
reactions were performed with a double-stranded oligonucleotide (top
strand, 5'-TTTTGGATTGAAGCCAATTATGATAA) of the NF-Y binding
basal transcription factor. For analysis of the on-rate, extracts were
incubated in binding buffer without labeled probe and aliquots of 9 µl (containing 2.5 µg of protein of whole-cell extract) were mixed
with NRE probe (104 cpm) and incubated for the specified
time. At the end of the incubation samples were loaded on a running
mobility shift gel.
Treatment with alkaline phosphatase.
Whole-cell extracts (5 µg) were equilibrated for 5 min at room temperature in
dephosphorylation buffer (25 mM HEPES-KOH [pH 7.9], 34 mM KCl, 50 mM
MgCl2). Alkaline phosphatase (0.1 U; Boehringer Mannheim)
was added on ice, and the mixture was incubated for 15 min. The
reaction was stopped by the addition of an equal volume of inhibitor
mixture (20 mM NaF, 20 mM sodium vanadate, 20 mM potassium
pyrophosphate, 200 µg of BSA per ml, 0.02% Nonidet P-40, 20%
glycerol, 5 mM DTT, 250 ng of sheared salmon sperm DNA per ml), and
then the NRE probe (20,000 cpm) was added. Incubation was continued for
20 min at room temperature, and protein-DNA complexes were separated as
described above. As a control for the different binding buffers, the
inhibitor mixture was added before incubation with the alkaline phosphatase.
Two-dimensional gel electrophoresis.
Isoelectric focusing of
P-19 nuclear extracts (5 µg) was carried out as specified by the
manufacturer (Bio-Rad) with vertical tube gels and equal volumes of two
ampholytes (pH 3 to 10 and pH 8 to 10 [Bio-Rad]). The second
dimension consisted of SDS-polyacrylamide gel electrophoresis (PAGE) in
a 10% polyacrylamide gel. Separated proteins were electroblotted onto
nitrocellulose filters, and the Sp1 protein detected with Sp1-specific
antibodies (see below) followed by horseradish peroxidase-linked
protein A. The complexes were detected with chemiluminescence reagents
as specified by the manufacturer (Amersham).
Western and Southwestern blots.
Samples of a P-19 nuclear
extract (in triplicate, 60 µg each) were separated by gel
electrophoresis (8% acrylamide) under reducing conditions and
transferred to nitrocellulose filters. The filter was cut to allow each
set of samples to be probed with either antibody or a radiolabeled
probe. For Western analysis, the blot was washed once in TBST buffer
(10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05% Tween 20) and blocked
for 1 h at room temperature in TBST buffer containing 5% milk.
The blot was subsequently incubated with the Sp1-specific antibody (1 µg/ml) in TBST buffer containing 5% milk. For Southwestern analysis,
the membranes were washed twice with renaturing buffer (20 mM HEPES-KOH
[pH 7.9], 3 mM MgCl2, 40 mM KCl, 10 mM
-mercaptoethanol, 80 µM ZnSO4) and subsequently blocked for 1 h with 20 mM HEPES-KOH (pH 7.9) containing 4% milk. The membranes were equilibrated in Southwestern binding buffer (10 mM
HEPES-KOH [pH 7.9], 70 mM NaCl, 1 mM DTT, 0.3 mM MgCl2, 0.1% Triton X-100, 60 µg of BSA per ml, 37.5 µg of sheared salmon sperm DNA per ml) and NRE probe (double-stranded oligonucleotide labeled with Klenow fragment and [
-32P]ATP) was added
for a 3-h incubation at room temperature. As a control, twofold excess
cold NRE in binding buffer was incubated for 1 h prior to probe
addition. Finally, the membranes were washed twice for 5 min at room
temperature with binding buffer containing 0.01% Triton X-100 and autoradiographed.
In-gel kinase assay.
Nuclear extracts were separated on a
10% polyacrylamide gel containing 0.2 mg of GST-Sp1 or GST protein
alone as control per ml. GST fusion proteins were affinity purified
over a column of glutathione-agarose. The gels were washed in 50 mM
HEPES-NaOH (pH 7.5) containing 20% isopropanol and denatured by two
washes in buffer I (50 mM HEPES [pH 7.5], 5 mM
-mercaptoethanol)
and two washes in buffer I containing 50 mM urea. Stepwise renaturation was performed with buffer I containing 0.02% Tween 20, with a final
overnight wash in the same buffer. Kinase reactions were performed in
kinase buffer (20 mM HEPES-NaOH [pH 7.5], 20 mM MgCl2, 2 mM DTT, 20 µM ATP, 5 µCi of [
-32P]ATP per ml) for
2 h at 30°C, and the gels were washed several times with a
mixture containing 5% trichloroacetic acid and 1% sodium
pyrophosphate, dried, and autoradiographed.
Metabolic labeling with [32P]orthophosphate and
immunoprecipitation.
P-19 cells were grown in 10-cm plates to 70 to 80% confluence. The cells were washed three times and incubated for
2 h in phosphate-free Dulbecco MEM (Sigma) containing 5% dialyzed
FCS. The medium was then changed to phosphate-free medium containing 0.5 mCi of [32P]orthophosphate (Amersham) per ml. At
4 h later, the cells were treated for 30 min with NDF
(100 ng/ml) or left untreated. All subsequent steps were carried out on ice
with ice-cold buffers. The cells were washed three times with phosphate
wash buffer, scraped into 500 µl of RIPA buffer (50 mM HEPES-KOH,
[pH 7.9], 150 mM NaCl, 2 mM EDTA [pH 8.0], 10% glycerol, 0.1%
SDS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 50 mM
-glycerophosphate, 1 mM sodium orthovanadate, 10 mM NaF, 400 nM
okadaic acid, 10 mM K2HPO4, 1 mM PMSF, 1 µg each of
aprotinin, leupeptin, and pepstatin per ml), and incubated for 20 min
on ice. Following a 20-min centrifugation at 14,000 × g, the supernatant was transferred to a fresh microcentrifuge tube
and the extract was precleared with 25 µl of protein A-Sepharose for
30 min with vigorous shaking. The beads were pelleted
(12,000 × g for 2 min), the supernatant was
transferred to a new tube, and 25 µl of protein A-Sepharose beads
conjugated to Sp1- or Egr1-specific antibodies (rabbit polyclonal
antibodies; Santa Cruz) was added. Immunoprecipitation was performed
for 2 h at 4°C with vigorous shaking, after which the
immunoprecipitated proteins were washed five times with RIPA buffer. At
the last wash, the beads were transferred to a new tube, resuspended in
30 µl of 2× protein-sample buffer (120 mM Tris-HCl [pH 6.8], 10%
glycerol, 3% SDS, 20 mM DTT, 0.4% bromophenol blue), and boiled for 5 min. The samples were separated by SDS-PAGE (7.5% acrylamide),
transferred to nitrocellulose and autoradiographed. Later, the
membranes were blocked and Western blotted as described above, except
that the anti-Sp1 antibody was of goat origin (Santa Cruz) and the
secondary antibody used was an anti-goat horseradish
peroxidase-conjugated antibody (Jackson Immunoresearch Laboratories,
Inc.).
 |
RESULTS |
Identification of an NDF-regulated DNA sequence in the promoters of
genes encoding AChR
and
subunits and NT-3.
To identify an
NDF-regulated sequence element, we compared the structures (Fig.
1A) and nucleotide sequences (Fig. 1B) of the promoters of the four genes known to be transcriptionally activated
by NDF; these are the genes encoding the rat and murine
subunits
and the murine
subunit of the AChR (5, 12, 32, 60), and
NT-3 (64). The promoters of both the
and
subunits contain a region sufficient for muscle-specific and NDF-specific regulation (12, 32). Moreover, it has been demonstrated that an E box (Fig. 1A) in the AChR
subunit gene is important for muscle-specific transcription whereas it is dispensable for induction by NDF (12). Regulation of the AChR
subunit gene
provides a particularly useful model for transsynaptic induction, since it is the only subunit that exhibits strict spatial regulation; the
,
,
, and
subunits are regulated by mechanisms that also allow expression outside the synaptic region under certain conditions. We identified a common 20-bp sequence in the enhancers of the AChR
and
subunits and in the upstream region of the NT-3 gene and
hypothesized that this sequence element is important for the observed
NDF-mediated induction of gene expression. To test this prediction, we
placed the full promoter sequence (228 bp) of the rat AChR
subunit
(18) upstream of a reporter plasmid, construct p
(
228/+25)-SEAP. Another reporter plasmid, containing three copies
of the suspected 20-bp sequence placed upstream of a luciferase gene
[plasmid construct p(NRE)×3-LUC] was also constructed. P-19 teratocarcinoma cells were separately transfected in triplicate with
the two reporter plasmids, as well as with a
-galactosidase plasmid,
which served as an internal control for all transfection assays. As
predicted, stimulation of the transfected P-19 cells with NDF
resulted in significant induction of both reporter genes (Fig. 1C): in
the context of the full-length promoter-enhancer, p
(
228/+25)-SEAP,
NDF was able to elevate SEAP activity two- to fourfold (Fig. 1C, left).
Moreover, the shared 20-bp sequence was sufficient to mediate the
effect of NDF on luciferase expression (Fig. 1C, center).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
Mapping of the NRE in the promoter of the AChR gene.
(A) Minimal promoter regions needed for muscle-specific expression of
the rat AChR gene (nucleotides 185 to +25), the mouse AChR gene ( 151 to +84), and the mouse AChR gene ( 148 to +24), as
well as the region in the promoter of the NT-3 gene encompassing the
putative NRE. The E-box element, which confers muscle-specific
expression, is indicated by a shaded box, and the region that confers
responsiveness to neuregulin is indicated by a solid box; arrows within
the boxes denote the orientation of this element. The mRNA start sites
are indicated by large arrows. (B) Sequence comparison of the CA-rich
elements found in the promoters of the NDF-inducible genes (asterisks
indicate bases that are strictly conserved). Also shown is the sequence
of an oligonucleotide (NRE Oligo) that we used to construct a reporter
plasmid and perform the EMSA. A mutation we introduced in the rat AChR
reporter is also listed (Rat AChR mut). (C) NDF-induced
transcriptional activation through NRE. The following constructs were
used to assay transcriptional activation of reporter genes (to
cotransfect P-19 cells together with a -galactosidase reporter as an
internal control): a minimal promoter of the rat AChR gene fused to
the SEAP gene [p ( 228/+25)-SEAP], three copies of the NRE
oligonucleotide cloned upstream of a luciferase reporter gene
[p(NRE)×3-LUC], and two versions, a wild-type and a mutant form (Rat
AChR mut [B]), of p ( 228/+25)-SEAP. At 24 h
posttransfection, cells were untreated ( ) or treated (+) with NDF
(100 ng/ml). At 16 h later, the cells were harvested for
luciferase and -galactosidase assays, or their medium was assayed
for SEAP activity. Signals obtained with the reporter genes were
normalized to -galactosidase activity.
|
|
To further establish the function of this element as an NDF-responsive
site, two of its conserved cytosines were mutated to
thymidines (Fig.
1B, Rat AChR

mut) in the context of the full-length
AChR

promoter. The mutated reporter construct was used in parallel
transfection experiments with the wild-type reporter construct
(Fig.
1C, right). The results of these experiments indicated that
the mutated
AChR

reporter either was completely unresponsive
to induction by
NDF (Fig.
1C, right) or retained very low activity
(data not shown),
thus establishing the short sequence as an essential
part of an
NRE.
Identification of NRE-binding complexes whose activation is induced
by several ligands.
EMSA was used to study the NDF-mediated
induction of protein-DNA complexes on the NRE. Whole-cell extracts were
prepared from different cell types, after treatment for various time
intervals with NDF, and incubated with a radiolabeled NRE
oligonucleotide (Fig. 1B). As a control for equal gel loading, we used
a NF-Y oligonucleotide as a probe for the NF-Y binding nuclear factor (Fig. 2B lanes 4 to 6). Two DNA-protein
complexes were detected following a 30-min treatment with NDF in
several cell lines (Fig. 2): P-19 teratocarcinoma cells (expressing
ErbB-1, ErbB-2, and ErbB-3), T47D breast tumor cells (expressing all
four ErbBs), and HeLa human cervical carcinoma cells (expressing ErbB-1
and ErbB-4), and others (data not shown). The kinetics of induction of
NRE binding activity differed; in both P-19 and HeLa cells, maximal
induction was observed at 30 min after NDF addition, whereas in T47D
cells, maximal induction was seen only after 2 h, but it persisted
longer. Furthermore, the intensity of the faster-migrating complex
(Fig. 2A) differed among the cell lines we tested; its induction was
relatively weak in P-19 cells whereas the intensities of the two bands
were comparable in T47D and HeLa cells. In conclusion, the induction of
NRE binding complexes by NDF appeared rapid, specific, and cell type
independent and thus may serve to regulate the transcription of other
genes by NDF.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 2.
NDF and EGF induce the formation of two NRE binding
complexes. (A) An oligonucleotide duplex (top strand sequence,
5'-TCGACTGCCACCCCCACCCCCACATCACC-3') was used as a probe and
incubated without ( ) or with 5 µg of whole-cell extract prepared
from P-19, T47D, or HeLa cells. The cells were untreated (N) or treated
for the indicated time intervals with NDF or EGF, as indicated, and
NRE binding was assayed by EMSA. Arrowheads indicate the positions of
the two protein-DNA complexes. Note that the complex whose mobility is
greater (open arrowhead) is absent in P-19 cells. (B) Whole-cell
extracts prepared from NDF-treated or untreated P-19 cells were used
for EMSA with the NRE oligonucleotide (lanes 1 to 3) or with the NF-Y
oligonucleotide probe as a control (lanes 4 to 6). Note the absence of
an NDF effect on NF-Y.
|
|
Similar to NDF, which binds to both ErbB-3 and ErbB-4, EGF, a ligand
for ErbB-1, was able to induce a similar pattern of DNA-protein
complexes (Fig.
2). However, the induction of complex formation
was
weaker than with NDF. EGF was thus used in transfection assays
with the
p

(

228/+25)-SEAP reporter to test its ability to induce
transcription. We found that the induction of SEAP activity by
EGF was
very low (data not shown), which may reflect the significantly
lower
induction of DNA binding as measured by EMSA. To extend
this
observation to additional growth factors, P-19 and T47D cells
were
treated for 30 min with several other ligands. The stem cell
factor
(SCF/c-Kit ligand) and the tumor-promoting phorbol ester
tetradecanoyl
phorbol acetate (TPA) were able to induce the formation
of the two DNA
binding complexes in P-19 cells. The effect of
SCF was much lower than
that of TPA, and an SCF-related factor,
platelet-derived growth factor,
was inactive in this cell system.
In addition, unlike NDF, which
induced primarily the slow-migrating
complex, both DNA-protein
complexes were induced to a similar
extent by SCF and TPA and a third,
intermediate, band was also
detectable upon treatment with these two
factors (Fig.
3). In
T47D cells, both EGF
and tumor necrosis factor were able to induce
the NRE-specific
DNA-protein complex to a level similar to that
induced by NDF whereas
the basic fibroblast growth factor and
alpha interferon exerted no
effect (Fig.
3). Thus, induction of
NRE binding activity is shared by
several but not all of the growth
factors tested. However, the levels
and relative inductions of
the two complexes varied.

View larger version (72K):
[in this window]
[in a new window]
|
FIG. 3.
Growth factor induction of protein-DNA complexes on the
NRE probe. P-19 (left) or T47D (right) cells were treated for 30 min
with the indicated growth factors or for 2 h with TPA, and
whole-cell extracts were prepared. Extracts were incubated with a
labeled NRE probe, and protein-DNA complexes were separated on a
nondenaturing polyacrylamide gel. The arrows denote the positions of
the free oligonucleotide probe, and the arrowheads denote the positions
of protein-DNA complexes (a slow-migrating complex [closed arrowhead]
and a fast-migrating complex [open arrowhead]). Abbreviations: NS,
nonstimulated; PDGF, platelet-derived growth factor; SCF, stem cell
factor; TNF, tumor necrosis factor; bFGF, basic fibroblast growth
factor; INF , alpha interferon.
|
|
The DNA-binding protein that is activated by NDF
is the
transcription factor Sp1.
NDF
induces transcriptional
activation from the NRE site, as well as complex formation on this DNA
sequence. To identify the factor(s) that binds to this site, we made
use of unlabeled competitor oligonucleotides carrying consensus
cytosine-rich binding elements for several known transcription factors.
T47D cells were selected for this assay since in these cells the two
complexes were comparably induced by NDF (Fig. 2 and 3). Whole-cell
extracts of T47D cells were incubated with 100- and 500-fold molar
excesses of various unlabeled competitor oligonucleotides, and NRE
binding activity was tested by EMSA (Fig.
4A). Since EGF treatment of A-431 cells
results in the phosphorylation and subsequent nuclear localization of
the STAT-1 transcription factor, which enables it to bind to the
cognate response element, the gamma interferon activation site
(56), we tested the gamma interferon activation site
oligonucleotide. However, this DNA element was unable to displace the
NDF-induced complexes formed on the NRE oligonucleotide (Fig. 4A, lanes
10 and 11). Similarly, the AP-2 response element, a CA-rich sequence
specific for the AP-2 family of transcription factors (66),
chased neither protein-DNA complex (compare lanes 7 and 8 with lane 9).
However, a consensus Sp1 element, a GC-rich sequence (41),
specifically bound to the slower-migrating complex (compare lanes 3 and
4 with lane 9). In fact, the Sp1 consensus oligonucleotide more
efficiently abolished the formation of the slower-migrating complex
than did an unlabeled NRE probe (compare lanes 1 and 2 with lanes 3 and
4) (data not shown), indicating that the NRE-bound complex interacts
more tightly with the consensus Sp1 sequence. A mutated Sp1
oligonucleotide, carrying a point mutation which abolishes binding by
Sp1 (41), was unable to compete for the slower-migrating
complex (lanes 5 and 6). Thus, the slower-migrating complex probably
consists of Sp1 or another member of the Sp1 family that shares DNA
binding specificity. To identify the specific member, we tried to
retard the electrophoretic mobility of the NRE-protein complex with an
Sp1-specific antibody. The antibody we used is directed against a
region of Sp1, which differs between the Sp family members. Supershift
analysis performed with whole extracts of P-19 and T47D cells indicated
that the NRE-bound protein is indeed Sp1 (Fig. 4B): the antibody was
specifically able to shift the upper band. A control preimmune serum or
an Sp3-specific antibody displayed no effect when similarly tested (Fig. 4B, lanes 3 and 6) (data not shown). Since a reporter construct carrying a mutation in the NRE was not inducible by NDF in transfection assays, and the basal transcription activity was not compromised (Fig.
1C), we concluded that Sp1 is essential for AChR
induction by NDF
but not for basal promoter activity.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 4.
Identification of factors interacting with the NRE. (A)
Competition between NRE and consensus oligonucleotides. Whole-cell
extracts were prepared from NDF -treated T47D cells and incubated
with the NRE probe in the absence ( ) or presence of the indicated
unlabeled competitor oligonucleotides at either 100-fold excess (lanes
1, 3, 5, 7, and 10) or 500-fold excess (lanes 2, 4, 6, 8, and 11). An
arrow denotes the position of the free NRE probe, and arrowheads denote
the positions of the two protein-DNA complexes (the solid arrowhead
indicates the slower-migrating complex). (B) The slower-migrating
protein-DNA complex is supershifted with an Sp1-specific antibody.
Whole-cell extracts prepared from EGF-treated P-19 cells or NDF-treated
T47D cells were preincubated with an Sp1-specific antibody ( Sp1). As
a control, extracts were treated with a preimmune serum (PI) or with no
antibody ( ). A labeled NRE probe was then added, and protein-DNA
complexes were separated on nondenaturing polyacrylamide gels. The
positions of the Sp1-specific complex (solid arrowhead) and the
supershifted complex (hatched arrowhead) are marked. Note that the
lower NRE complex underwent no supershift.
|
|
NDF-mediated induction of complex formation on the NRE is dependent
on protein phosphorylation.
Regulation of transcription factor
activity can result from induction of de novo protein synthesis or from
modification, primarily phosphorylation (27), of an existing
protein. Because Sp1 is a heavily phosphorylated phosphoprotein which
is ubiquitously expressed in all cell lines and tissues
(34), we postulated that the induction of Sp1 binding
activity is due to protein phosphorylation or dephosphorylation events.
Cell treatment with a general inhibitor of tyrosine kinases, genistein
(49), abolished NDF induction of the slower-migrating
complex while leaving unaffected the activation of the faster-migrating
species (Fig. 5A [left], compare lanes 6 and 7 with lanes 2 and 3). By contrast, an inhibitor specific to ErbB
tyrosine kinases, tyrphostin AG-2002 (21), inhibited the
induction of both protein-DNA complexes (Fig. 5A [right], lanes 7 and
8). An inhibitor of PKC, GF109203X, an activator of the protein kinase
A signaling pathway, and forskolin had no effect on complex formation.
Wortmannin, a phosphatidylinositol 3'-kinase inhibitor, lowered both
basal and NDF-induced levels of the mobility shifts. However, the
induction by NDF was still detectable. By contrast, treatment with
okadaic acid, a potent inhibitor of protein phosphatases
(13), strongly inhibited the induction of both NRE-protein
complexes as determined by EMSA (Fig. 5A [right], compare lanes 3 through 6 with lanes 1 and 2). The inhibitory concentration of okadaic
acid (0.5 µM) (Fig. 5A, left) can specifically inhibit protein
phosphatase 2A (PP2A), implying that PP2A acts as a positive regulator
of signaling upstream of Sp1 activation by NDF.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 5.
Phosphorylation events are important for the regulation
of Sp1 binding to the NRE site. (A) Effects of kinase and phosphatase
inhibitors on NRE binding activity in NDF -treated T47D cells. Prior
to EMSA with an NRE probe, the cells were preincubated for 20 min with
the inhibitors GF109203X (GF109, a protein kinase C-specific
inhibitor), genistein (a general inhibitor of tyrosine kinases),
forskolin (an inhibitor of cyclic AMP phosphodiesterases), okadaic acid
(OA, an inhibitor of protein phosphatase 2A), AG2002 (an inhibitor of
the ErbB tyrosine kinase activity), and wortmannin (a
phosphatidylinositol 3'-kinase inhibitor) and then treated with NDF.
Control cultures were not treated with an inhibitor. The positions of
the two protein-DNA complexes are denoted by arrowheads (closed
arrowhead, Sp1-specific complex; open arrowhead, faster-migrating
complex). As a control, EMSA was performed with the NF-Y probe (lower
panel). (B) Inhibition of Sp1 DNA binding by in vitro treatment with
CIP. The NRE (upper panel) and NF-Y (lower panel) probes were incubated
with 5 µg of extracts prepared from P-19 cells that were incubated
for the indicated time intervals with NDF (N). Control cultures were
not treated with a growth factor ( ). Prior to EMSA, extracts were
incubated with CIP and then the phosphatase was inhibited by addition
of specific inhibitors (a mixture of NaF, sodium vanadate, and
potassium pyrophosphate [lanes 4 and 5]). Alternatively, the
inhibitors were added prior to treatment with CIP (lanes 2 and 3). The
position of the Sp1-specific complex is indicated by an arrowhead. (C)
Sp1 is a phosphoprotein whose phosphorylation is increased by NDF. P-19
cells were preincubated with a medium containing
[32P]orthophosphate and then treated (lanes 1 and 3) or
not treated (lanes 2 and 4) with NDF. Whole-cell extracts were prepared
and incubated with an anti-Sp1 antiserum (lanes 1 and 2) or an
anti-Egr1 antibody (lanes 3 and 4). The immunoprecipitates were
resolved by SDS-PAGE and electrophoretically transferred to a
nitrocellulose filter. The filter was subjected to autoradiography
(inset) and then immunoblotted with an antibody to Sp1 (data not
shown). Both signals were quantified, and their ratio is presented in a
histogram. Numbers below the bars correspond to gel lanes. (D) Analysis
of NDF-induced phosphorylation of Sp1 by two-dimensional gel
electrophoresis. Nuclear extracts (5 µg of protein) were prepared
from untreated (Control), or P-19 cells treated with 100 ng of NDF
per ml. As a control, a mixture of the two nuclear extracts (2.5 µg
each) was analyzed (MIX). Extracts were separated by isoelectric
focusing in the first dimension (pH values are indicated) and by
SDS-PAGE in the second dimension (the locations of marker proteins are
indicated in kilodaltons). The proteins were then transferred to
nitrocellulose filters, and the Sp1 protein was detected by
immunoblotting with an anti-Sp1 antibody.
|
|
We next examined the possibility that the NRE-bound complex is
phosphorylated and that this protein phosphorylation is essential
for
DNA binding. To test this paradigm, we treated whole-cell
extracts,
which were prepared from growth factor-treated cells,
with a
nonspecific phosphatase (calf intestinal phosphatase, CIP)
and then
determined how this affected the EMSA pattern. As a control
for the
difference in buffer conditions, extracts were treated
with CIP in the
presence of specific inhibitors. In addition,
as a specificity control
CIP-treated extracts were incubated with
the NF-Y response element. The
result of these analyses indicated
that protein dephosphorylation
inhibited the binding of both Sp1
and the faster-migrating complex
(Fig.
5B, compare lanes 3 and
5). CIP treatment did not compromise the
DNA binding activity
of the extract in a nonspecific manner, since
binding to the NF-Y
probe could still be detected (Fig.
5B,
bottom).
To determine if NDF induces an increase in Sp1 phosphorylation in
living cells, we incubated P-19 cells with radioactive orthophosphate,
stimulated the cells with NDF, and then determined the state of
Sp1
phosphorylation. Sp1 was immunoprecipitated from labeled cells,
subjected to SDS-PAGE, transferred to nitrocellulose membranes,
and
autoradiographed. As expected, Sp1 was phosphorylated in unstimulated
cells (Fig.
5C, inset, lane 1), but incubation with NDF for 30
min
moderately increased its phosphorylation (lane 2). By contrast,
the
state of phosphorylation of another zinc finger-containing
transcription factor, Egr-1, was not affected by NDF. Reblotting
of the
nitrocellulose filter with an anti-Sp1 antibody enabled
precise
quantification of Sp1 phosphorylation: a 50 to 60% increase
in Sp1
phosphorylation was determined. This moderate increase
is probably due
to the relatively high basal phosphorylation of
Sp1. Therefore,
NDF-induced phosphorylation was tested by an alternative
approach,
two-dimensional gel electrophoresis, which examines
the change in
isoelectric point due to phosphorylation. Nuclear
extracts were
prepared from untreated and NDF-treated P-19 cells
and resolved by
two-dimensional gel electrophoresis, which separates
proteins according
to their isoelectric point in the first dimension
and by their size in
the second dimension. Gel-separated proteins
were transferred to
nitrocellulose filters and immunoblotted with
an Sp1-specific antibody.
This analysis revealed that several
isoforms of Sp1 exist in
unstimulated cells, but NDF can induce
broadening of their pI range
toward the acidic pole (Fig.
5D),
consistent with the addition of
phosphate groups. Electrophoresis
of a mixture of extracts from treated
and untreated cells confirmed
the effect of NDF (Fig.
5D, bottom). We
estimate that approximately
half of the Sp1 molecules are modified upon
NDF treatment. In
addition, the appearance of the modified Sp1
suggested that more
than one phosphate group is attached to these
hyperphosphorylated
Sp1 molecules. In experiments whose results are not
presented,
we detected no tyrosine phosphorylation of Sp1, indicating
that
modification of this serine- and threonine-rich protein does not
affect its few tyrosine
residues.
NDF regulation of Sp1 binding activity is independent of monomeric
Sp1 DNA binding capacity.
The observed NDF-induced increase in Sp1
binding to the NRE may be attributed to a change in protein level or to
enhanced DNA binding capacity. To gain an insight into the underlying
mechanism, Western and Southwestern analyses were performed to
determine if there was a change in Sp1 protein levels or in its
capability to bind DNA. Immunoblotting of whole-cell extracts with
anti-Sp1 antibodies excluded the possibility that changes in protein
levels were responsible for increased binding of a protein complex to the NRE (Fig. 6A, left). Southwestern
analysis of the nuclear extracts with labeled NRE as a probe showed
that the binding of a monomeric Sp1 was not affected by NDF treatment
(Fig. 6A, center). However, NRE binding to an unidentified protein with
a molecular weight of approximately 45,000 was increased by NDF.
Nevertheless, combined treatment with NDF and okadaic acid failed to
affect the binding of either p45 or Sp1 (p110) to the NRE (Fig. 6A), although this treatment inhibited NDF-induced complex formation on the
NRE oligonucleotide in EMSA (Fig. 5A). The specificity of binding of
the labeled NRE probe to gel-separated proteins, including Sp1, was
evident from the right panel of Fig. 6A: an unlabeled NRE
oligonucleotide displaced the labeled probe from all protein bands.
Conceivably, although NDF increases the phosphorylation of Sp1, this
modification apparently regulates the oligomerization state of Sp1 or
its interaction with other proteins, since NRE binding of monomeric Sp1
was not altered.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 6.
Sp1 binding and kinetics of complex formation on the
NRE. (A) Southwestern analysis. Whole-cell extracts were prepared from
P-19 cells that were untreated ( ) or treated for 30 min with NDF .
A third culture was incubated for 20 min with okadaic acid (OA) prior
to treatment with NDF. Duplicate extracts (60 µg) were separated by
SDS-PAGE and then subjected to either Western blot analysis with an
antibody to Sp1 (left) or to Southwestern analysis with a labeled NRE
probe (center and right). For control of NRE binding specificity, the
Southwestern analysis was also performed in the presence of an excess
of the unlabeled NRE probe (right). The Sp1 band is labeled by an
arrowhead. (B) On-rate kinetics of complex formation on the NRE. Whole
P-19 cell extracts prepared from untreated (lanes 1 to 9) or
NDF-treated (lanes 10 to 18) cells were incubated in EMSA binding
buffer. Equal volumes were removed and incubated for the indicated time
intervals with a labeled NRE probe. At the end of the incubation,
samples were loaded on a running mobility shift gel. The positions of
the NRE-specific complexes are marked by a solid arrowhead (the
slowest-migrating complex), an open arrowhead, and brackets (the
fastest-migrating complex). Time is marked as seconds (") or minutes
('). Note that due to continuous electrophoresis while loading samples
on the gel, all of the bracket-labeled bands represent the same
complex.
|
|
To detect such Sp1-containing complexes following treatment with NDF,
an on-rate analysis was performed. Whole-cell extracts
were incubated
with the NRE probe for various time intervals (Fig.
6B). Two
significant differences between untreated and NDF-treated
extracts were
observed (Fig.
6B, lanes 1 to 9 and lanes 10 to
18, respectively).
First, at the shortest time intervals, NRE
binding to both the
slowest-migrating and fastest-migrating complexes
was already increased
by NDF (Fig.
6B). Second, upon longer incubation
with the NRE probe,
the two slower-migrating complexes displayed
higher stability in the
NDF-treated extracts (Fig.
6B). Thus,
NDF appears to induce complex
formation of Sp1 and other proteins
on the NRE
site.
An NDF-stimulatable kinase of approximately 60 kDa phosphorylates
Sp1 and is repressed by okadaic acid.
To test the scenario that
NDF increases the phosphorylation of Sp1, which in turn leads to
transactivation from the NRE, we analyzed extracts of NDF-treated P-19
cells by using an in-gel kinase assay. As a substrate for in-gel
phosphorylation, we used a recombinant Sp1 protein, in the form of a
fusion protein with GST. After denaturation and renaturation, the
gel-resolved proteins were incubated with [
-32P]ATP to
detect in situ the Sp1-specific kinase(s). Three major bands of kinase
activity were observed in the resolved extracts. Of these, a prominent
band of approximately 60 kDa was rapidly induced by NDF, and its
activity was sustained (Fig. 7). A second major protein band (ca. 84 kDa) was also detected in gels that were
polymerized in the presence of GST alone (data not shown), and thus it
was considered to be nonspecific for Sp1. Importantly, the observed
induction of the 60-kDa kinase activity by NDF was blocked by
pretreatment of cells with 0.5 µM okadaic acid (Fig. 7, compare lanes
2 and 7), in agreement with the inhibitory effect of okadaic acid on
Sp1 binding to the NRE (Fig. 5A). Interestingly, a third kinase band
(ca. 45 kDa) displayed sensitivity to okadaic acid and underwent weak
activation by NDF (Fig. 7), implying that it is functionally related to
the 60-kDa kinase. In conclusion, a renaturable Sp1-specific kinase,
whose activity is inducible by NDF, exists in P-19 cells. This kinase
may serve to transactivate Sp1 action at the NRE.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 7.
The kinase that enhances Sp1 binding to NRE is NDF
inducible and okadaic acid sensitive. P-19 cells were treated with
NDF for the indicated time intervals in the absence ( ) or presence
(+) of 0.5 µM okadaic acid (added 20 min prior to NDF ). Cell
extracts were then analyzed for kinase activity by using a recombinant
form of the human Sp1 protein and an in-gel kinase assay as detailed in
Materials and Methods. The position of the kinase which is induced by
NDF and inhibited by okadaic acid is marked by an arrow. The locations
of molecular weight marker proteins are indicated in thousands.
|
|
 |
DISCUSSION |
Sp1 binding to specific response elements and transactivation of
its transcriptional function are regulated by a variety of extracellular stimuli. Insulin-like growth factor I regulates the
elastin gene through disruption of Sp1 DNA binding (31), and
transforming growth factor
enhances transcription of both the
2(I) collagen gene (28) and the p15 cyclin-dependent
kinase inhibitor (42) through an Sp1 consensus site.
Likewise, EGF stimulation of the gastrin promoter is mediated by Sp1
(43). The present study extends this latter observation to
another growth factor of the EGF family, NDF. Our survey of other
EGF-like ligands implies that Sp1 mediates, to various extents,
transcriptional regulation by most, if not all, ligands of ErbB
receptors. In addition, cell lines expressing different combinations of
the four ErbB receptors were responsive to NDF and EGF, suggesting that
Sp1 acts downstream of all ErbB proteins (Fig. 2 and our unpublished
observations). Several independent lines of evidence suggest a role for
Sp1 in transmission of ErbB signals. (i) A full-length promoter
containing the Sp1 binding site, as well as a derivative 20-bp
sequence, can confer transcriptional activation by NDF of two reporter
genes in living cells (Fig. 1C). (ii) NDF treatment of living cells
increased the binding of a nuclear factor, which is recognized by
anti-Sp1 antibodies, to the minimal NRE sequence element (Fig. 2 and
4). (iii) the observation that NDF can elevate phosphorylation of Sp1
(Fig. 5C and D) indirectly supports the notion that this transcription
factor lies downstream to ErbB.
The sequence we identified as the NDF-regulated element differs from
the common consensus Sp1 binding sites, the GC or GT boxes
(33). Nevertheless, an NRE-related sequence, which contains three repeats of the element CCACCC, was identified as a
basal and an inducible sequence bound by Sp1 in the interleukin-6
promoter (35). Another CA-rich sequence, the retinoblastoma
control element, which is regulated by the retinoblastoma protein (Rb),
was localized to the promoters of several growth-regulatory genes, such
as c-fos and c-myc (52). This element
binds several transcription factors including Sp1 and Sp3 (36,
63) and, depending on the cellular context, will be repressed or
stimulated by Rb. Sp3 has been demonstrated to repress Sp1-mediated
transcription due to competition for Sp1 binding sites (25).
Thus, the effect of Rb may depend on the ratio between Sp1 and Sp3
molecules in a cell. Our preliminary analysis, however, did not detect
functional interaction of Rb and Sp1 at the NRE.
The slow kinetics of transactivation of Sp1 by NDF probably reflects
processing of the signal initiated by tyrosine phosphorylation of ErbBs
(Fig. 2). However, the exact molecular mechanism that leads to Sp1
activation remains unclear. Analyses of Sp1 structure and function have
revealed that the protein can be separated into discrete functional
domains: a DNA binding domain and four separate domains that govern
transcriptional activation (34). Our Southwestern analysis
implies that Sp1 transactivation may not be due to increased affinity
of the monomeric Sp1 DNA binding domain to the NRE (Fig. 6A). Sp1 binds
to a single GC box as a monomer. However, higher-order complexes
between Sp1 monomers are assembled via direct protein-protein interactions that do not involve additional contacts with DNA but
require the two N-terminal transactivation domains (47). Sp1
phosphorylation may circumvent the need for a high local protein concentration by increasing the affinity of protein-protein
interactions and thus facilitating the formation of Sp1 multimers on
DNA without a change in monomeric DNA binding affinity, as implied by
the Southwestern assay (Fig. 6A). Moreover, phosphorylation of Sp1 may
affect complex formation with other proteins, as suggested by the
on-rate analysis (Fig. 6B), resulting in the formation of an
Sp1-containing complex on the NRE site. GBF, a GC homopolymer binding
factor, was identified as a second factor that binds to the GC box
lying downstream of the E-box of the AChR
subunit (fastest-migrating complex in EMSA) (8). Interactions
between this factor and Sp1 may facilitate complex formation on the NRE in NDF-stimulated cells, thereby regulating transcription.
Pharmacological intervention of the signaling pathway leading to NRE
binding yielded some new information. Inhibition of tyrosine phosphorylation by using either the general inhibitor genistein or an
ErbB-specific tyrphostin efficiently reduced the NDF-dependent complex
formation on the NRE (Fig. 5A). This observation is consistent with the
requirement for tyrosine phosphorylation at the ErbB level and at the
linear cascade leading to MAPK activation. Indeed, MAPK has been
implicated in the regulation of two distinct subunits of the AChR by
the neuregulin isoforms AChR-inducing activity (57) and
heregulin (3). Inhibition of PKC did not affect Sp1 binding
to the NRE (Fig. 5A), although TPA, an agonist of PKC, effectively
transactivated Sp1 (Fig. 3). Similarly, a PKA-specific agonist exerted
no effect on the formation of the Sp1-NRE complex (Fig. 5A), although
it has been previously demonstrated that PKA can directly phosphorylate
Sp1 (53). Conceivably, the functional linkage of ErbBs to
Sp1 is mediated by MAPK but not by PKC or PKA, although these two
kinases may be involved in activation of Sp1 by alternative
extracellular stimuli.
The inhibitory effect of okadaic acid (Fig. 5A) is interesting in light
of the observations that dephosphorylation of Sp1 enhances its DNA
binding activity (39) and that treatment of leukemic cells
with okadaic acid enhances WAF1/CIP1 expression through Sp1 activation
(10). In both these cases, PP2A directly acted on Sp1,
whereas in the pathway linking NDF to Sp1, okadaic acid appears to act
upstream of Sp1. Several protein kinases were implicated in the
regulation of Sp1 activity, including a DNA-dependent protein kinase,
whose phosphorylation of Sp1 does not affect its transactivation or DNA
binding activity (29). In addition, both PKA (53)
and casein kinase II, which is inhibitory to Sp1 (4), were
implicated in previous studies. None of these kinases, however, appears
similar to the 60- to 65-kDa protein kinase activity that we detected
by using an in-gel kinase assay (Fig. 7). The identity of this
NDF-inducible protein kinase and the pathway leading to its activation
remain unclear. Nevertheless, the following sequence of events is
likely to precede the augmentation of Sp1 binding to the NRE: NDF
binding to an ErbB protein is followed by rapid stimulation of tyrosine
phosphorylation and stepwise activation of the cascade leading to MAPK
activation. The Sp1-specific protein kinase of 60 to 65 kDa is
presumably located downstream of one of these kinases.
Dephosphorylation by PP2A, or a related phosphatase, of one of the
kinases upstream of Sp1 presumably activates Sp1 phosphorylation.
Alternatively, it may be that PP2A dephosphorylates a site(s) in Sp1
which is required for activation of Sp1 in conjunction with
phosphorylation of a distinct site (Fig. 5C). Upon phosphorylation, this transcription factor may oligomerize or associate with another cellular component(s), leading to enhanced binding to the NRE.
Signaling by NDF, as well as by other EGF-like ligands, is funneled
into a complex signaling network that diversifies and tunes mitogenic
and differentiation signals downstream of the 10 homo- and
heterodimeric combinations of the four ErbB proteins (reviewed in
reference 2). Like its primitive versions in worms (38) and in flies (50), the mammalian ErbB
network acts primarily through the MAPK pathway. Our present results
imply that most dimers of ErbB proteins are coupled to Sp1
transactivation. Consistent with this notion, a Drosophila
zinc finger transcription factor, termed stripe, was shown to act
downstream of the insect homologue of ErbB proteins (20). In
addition, Krox-20 (61) and Egr-1 (40), two zinc
finger transcription factors distinct from Sp1, were shown to be under
transcriptional and translational control of NDF and EGF, respectively.
Conceivably, the signaling machinery downstream of ErbBs translates
extracellular signals into distinct gene expression programs by
controlling multiple zinc finger transcription factors. This mechanism
probably mediates the many inductive processes that are regulated by
NDF and ErbB proteins, including the interaction between nerve and
Schwann cells (45), the survival effect of nonneuronal cells
on neurons (64), mesenchyme-epithelial cell interactions in
parenchymal organs (67), and neurons and striated muscles at
the synapse site (19). This last example is better understood: in addition to zinc finger proteins (8), GABP, an Ets-like transcription factor, regulates spatial expression of the
nicotinic AchR at the neuromuscular synapse (54).
If all ErbB proteins are coupled to Sp1 activation, how is signal
specificity maintained? Specificity of gene expression may be conferred
by modifying the glycosylation (30) or phosphorylation (29) states of Sp1 or by tissue-specific expression of
components of the ErbB-Sp1 signaling module. However, the ubiquitous
expression of three of the four Sp1 proteins weakens the possibility
that spatial and temporal controls of Sp1 expression confer specificity to NDF signaling. Alternatively, Sp1 may act as a scaffolding protein
(9) that facilitates binding or enhances the transcriptional activation of additional transcription factors, whose expression is
less ubiquitous. Once again, transcription from the
and
subunits of the nicotinic AchR may serve as an example: in addition to
the NRE, these two promoters contain an E-box element (Fig. 1A) that
binds myogenic factors such as myogenin and Myf-5 (18). According to a recent report, regulation of the
subunit of the AchR
is under complex control by myogenic as well as nonmyogenic transcription factors, which include Sp1, Sp3, and three additional distinct factors (7). Recently, it has been shown that Sp1 may interact with histone deacetylases and thereby actively repress transcription. This interaction may be regulated by Sp1
phosphorylation, which will cause its dissociation from histone
deacetylases, thereby alleviating repression (59). Thus, Sp1
binding to the NRE may be part of a complex cascade of events leading
to transcriptional activation of NDF target genes in synergy with
tissue- and stage-specific factors.
 |
ACKNOWLEDGMENTS |
We thank V. Witzemann for the p(
228/+35)AChR
-CAT promoter
plasmid, Scott L. Friedman for the pCI-Sp1 plasmid, and Alexander Levitzki for tyrphostin AG2002.
This work was supported by grants from the National Cancer Institute of
the U.S. National Institutes of Health (grant CA-72981) and the Israel
Science Foundation administered by the Israel Academy of Sciences and Humanities.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biological Regulation, The Weizmann Institute of Science, Rehovot
76100, Israel. Phone: 972-8-9343974. Fax: 972-8-9344116. E-mail:
liyarden{at}weizmann.weizmann.ac.il.
 |
REFERENCES |
| 1.
|
Alroy, I.,
T. L. Towers, and L. P. Freedman.
1995.
Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor.
Mol. Cell. Biol.
15:5789-5799[Abstract].
|
| 2.
|
Alroy, I., and Y. Yarden.
1997.
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions.
FEBS Lett.
410:83-86[Medline].
|
| 3.
|
Altiok, N.,
X. Altiok, and J. P. Changeux.
1997.
Heregulin-stimulated acetylcholine receptor gene expression in muscle: requirement for MAP kinase and evidence for a parallel inhibitory pathway independent of electrical activity.
EMBO J.
16:717-725[Medline].
|
| 4.
|
Armstrong, S. A.,
D. A. Barry,
R. W. Leggett, and C. R. Mueller.
1997.
Casein kinase II-mediated phosphorylation of the C terminus of Sp1 decreases its DNA binding activity.
J. Biol. Chem.
272:13489-13495[Abstract/Free Full Text].
|
| 5.
|
Baldwin, T. J., and S. J. Burden.
1988.
Isolation and characterization of the mouse acetylcholine receptor delta subunit gene: identification of a 148-bp cis-acting region that confers myotube-specific expression.
J. Cell Biol.
107:2271-2279[Abstract/Free Full Text].
|
| 6.
|
Ben-Baruch, N.,
I. Alroy, and Y. Yarden.
1997.
Developmental and physiological roles of ErbB receptors and their ligands in mammals, p. 145-168.
In
R. B. Dickson, and D. S. Salomon (ed.), Hormones and growth factors in development and neoplasia. Kluwer Academic Publishers, Boston, Mass.
|
| 7.
|
Bessereau, J. L.,
V. Laudenbach,
C. Le Poupon, and J. P. Changeux.
1998.
Nonmyogenic factors bind nicotinic acetylcholine receptor promoter elements required for response to denervation.
J. Biol. Chem.
273:12786-12793[Abstract/Free Full Text].
|
| 8.
|
Bessereau, J. L.,
D. Mendelzon,
C. LePoupon,
M. Fiszman,
J. P. Changeux, and J. Piette.
1993.
Muscle-specific expression of the acetylcholine receptor alpha-subunit gene requires both positive and negative interactions between myogenic factors, Sp1 and GBF factors.
EMBO J.
12:443-449[Medline].
|
| 9.
|
Bidwell, J. P.,
A. J. Van Wijnen,
E. G. Fey,
S. Dweretzky,
S. Penman,
J. L. Stein,
J. B. Lian, and G. S. Stein.
1993.
Osteocalcin gene promoter-binding factors are tissue-specific nuclear matrix components.
Proc. Natl. Acad. Sci. USA
90:3162-3166[Abstract/Free Full Text].
|
| 10.
|
Biggs, J. R.,
J. E. Kudlow, and A. S. Kraft.
1996.
The role of transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells.
J. Biol. Chem.
271:901-906[Abstract/Free Full Text].
|
| 11.
|
Burden, S., and Y. Yarden.
1997.
Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis.
Neuron
18:847-855[Medline].
|
| 12.
|
Chu, G. C.,
L. M. Moscoso,
M. X. Sliwkowski, and J. P. Merlie.
1995.
Regulation of the acetylcholine receptor epsilon subunit gene by recombinant ARIA: an in vitro model for transynaptic gene regulation.
Neuron
14:329-339[Medline].
|
| 13.
|
Cohen, P.,
D. Schelling, and M. Starck.
1989.
Remarkable similarities between yeast and mammalian protein phosphatases.
FEBS Lett.
250:601-606[Medline].
|
| 14.
|
Courey, A. J.,
D. A. Holtzman,
S. P. Jackson, and R. Tjian.
1989.
Synergistic activation by the glutamine-rich domains of human transcription factor Sp1.
Cell
59:827-836[Medline].
|
| 15.
|
Daniel, S.,
S. Zhang,
R. A. DePaoli, and K. H. Kim.
1996.
Dephosphorylation of Sp1 by protein phosphatase 1 is involved in the glucose-mediated activation of the acetyl-CoA carboxylase gene.
J. Biol. Chem.
271:14692-14697[Abstract/Free Full Text].
|
| 16.
|
Datta, P. K.,
P. Raychaudhuri, and S. Bagchi.
1995.
Association of p107 with Sp1: genetically separable regions of p107 are involved in regulation of E2F- and Sp1-dependent transcription.
Mol. Cell. Biol.
15:5444-5452[Abstract].
|
| 17.
|
Dong, Z.,
A. Brennan,
N. Liu,
Y. Yarden,
G. Lefkowitz,
R. Mirsky, and K. R. Jessen.
1995.
Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat Schwann cell precursors.
Neuron
15:585-596[Medline].
|
| 18.
|
Durr, I.,
M. Numberger,
C. Berberich, and V. Witzemann.
1994.
Characterization of the functional role of E-box elements for the transcriptional activity of rat acetylcholine receptor epsilon-subunit and gamma-subunit gene promoters in primary muscle cell cultures.
Eur. J. Biochem.
224:353-364[Medline].
|
| 19.
|
Falls, D. L.,
K. M. Rosen,
G. Corfas,
W. S. Lane, and G. D. Fischbach.
1993.
ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family.
Cell
72:801-815[Medline].
|
| 20.
|
Frommer, G.,
G. Vorbruggen,
G. Pasca,
H. Jackle, and T. Volk.
1996.
Epidermal egr-like zinc finger protein of Drosophila participates in myotube guidance.
EMBO J.
15:1642-1649[Medline].
|
| 21.
|
Gazit, A.,
J. Chen,
H. App,
G. McMahon,
P. Hirth,
I. Chen, and A. Levitzki.
1996.
Tyrphostins IV highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines.
Bioorg. Med. Chem.
4:1203-1207[Medline].
|
| 22.
|
Gill, G.,
E. Pascal,
Z. H. Tseng, and R. Tjian.
1994.
A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts the dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation.
Proc. Natl. Acad. Sci. USA
91:192-196[Abstract/Free Full Text].
|
| 23.
|
Greenwel, P.,
W. Hu,
R. A. Kohanski, and F. Ramirez.
1995.
Tyrosine dephosphorylation of nuclear proteins mimics transforming growth factor beta 1 stimulation of alpha 2(I) collagen gene expression.
Mol. Cell. Biol.
15:6813-6819[Abstract].
|
| 24.
|
Hagen, G.,
S. Muller,
M. Beato, and G. Suske.
1992.
Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes.
Nucleic Acids Res.
20:5519-5525[Abstract/Free Full Text].
|
| 25.
|
Hagen, G.,
S. Muller,
M. Beato, and G. Suske.
1994.
Sp1-mediated transcriptional activation is repressed by Sp3.
EMBO J.
13:3843-3851[Medline].
|
| 26.
|
Holmes, W. E.,
M. X. Sliwkowski,
R. W. Akita,
W. J. Henzel,
J. Lee,
J. W. Park,
D. Yansura,
N. Abadi,
H. Raab,
G. D. Lewis,
M. Shepard,
W. I. Wood,
D. V. Goeddel, and R. L. Vandlen.
1992.
Identification of heregulin, a specific activator of p185erbB2.
Science
256:1205-1210[Abstract/Free Full Text].
|
| 27.
|
Hunter, T., and M. Karin.
1992.
The regulation of transcription by phosphorylation.
Cell
70:375-387[Medline].
|
| 28.
|
Inagaki, Y.,
S. Truter, and F. Ramirez.
1994.
TGF- stimulates 2(I) collagen gene expression through a cis-acting element that contains an Sp1-binding site.
J. Biol. Chem.
269:14828-14834[Abstract/Free Full Text].
|
| 29.
|
Jackson, S. P.,
J. J. MacDonald,
S. Lees-Miller, and R. Tjian.
1990.
GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase.
Cell
63:155-165[Medline].
|
| 30.
|
Jackson, S. P., and R. Tjian.
1988.
O-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation.
Cell
55:125-133[Medline].
|
| 31.
|
Jensen, D. E.,
C. B. Rich,
A. J. Terpstra,
S. R. Farmer, and J. A. Foster.
1995.
Transcriptional regulation of the elastin gene by insulin-like growth factor-I involves disruption of Sp1 binding. Evidence for the role of Rb in mediating Sp1 binding in aortic smooth muscle cells.
J. Biol. Chem.
270:6555-6563[Abstract/Free Full Text].
|
| 32.
|
Jo, S. A.,
X. Zhu,
M. A. Marchionni, and S. J. Burden.
1995.
Neuregulins are concentrated at nerve-muscle synapses and activate ACh- receptor gene expression.
Nature
373:158-161[Medline].
|
| 33.
|
Kadonaga, J. T.,
K. R. Carner,
F. R. Masiarz, and R. Tjian.
1987.
Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA-binding domain.
Cell
51:1079-1090[Medline].
|
| 34.
|
Kadonaga, J. T.,
A. J. Courey,
J. Ladika, and R. Tijan.
1988.
Distinct regions of Sp1 modulate DNA binding and transcriptional activation.
Science
242:1566-1570[Abstract/Free Full Text].
|
| 35.
|
Kang, S.-H.,
D. A. Brown,
I. Kitajima,
X. Xu,
O. Heindenreich,
S. Gryaznov, and M. Nerenberg.
1996.
Binding and functional effects of transcriptional factor Sp1 on the murine interleukin-6 promoter.
J. Biol. Chem.
271:7330-7335[Abstract/Free Full Text].
|
| 36.
|
Kim, S.-J.,
U. S. Onwuta,
Y. I. Lee,
R. Li,
M. R. Botchan, and P. D. Robbins.
1992.
The retinoblastoma gene product regulates Sp1-mediated transcription.
Mol. Cell. Biol.
12:2455-2463[Abstract/Free Full Text].
|
| 37.
|
Kingsley, C., and A. Winoto.
1992.
Cloning of GT box binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression.
Mol. Cell. Biol.
12:4251-4261[Abstract/Free Full Text].
|
| 38.
|
Kornfeld, K.
1997.
Vulval development in Caenorbaditis elegans.
Trends Genet.
13:55-61[Medline].
|
| 39.
|
Leggett, R. W.,
S. A. Armstrong,
D. Barry, and C. R. Mueller.
1995.
Sp1 is phosphorylated and its DNA binding activity down-regulated upon terminal differentiation of the liver.
J. Biol. Chem.
270:25879-25884[Abstract/Free Full Text].
|
| 40.
|
Lemaire, P.,
C. Vesque,
J. Schmitt,
H. Stunnenberg,
R. Frank, and P. Charnay.
1990.
The serum-inducible mouse gene Krox-24 encodes a sequence-specific transcriptional activator.
Mol. Cell. Biol.
10:3456-3467[Abstract/Free Full Text].
|
| 41.
|
Letovsky, J., and W. S. Dynan.
1989.
Measurment of the binding of transcription factor Sp1 to a single GC box recognition sequence.
Nucleic Acids Res.
17:2639-2673[Abstract/Free Full Text].
|
| 42.
|
Li, J.-M.,
M. A. Nicholas,
S. Chandrasekharan,
Y. Xiong, and X.-F. Wang.
1995.
Transforming growth factor activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site.
J. Biol. Chem.
270:26750-26753[Abstract/Free Full Text].
|
| 43.
|
Merchant, J. L.,
A. Shiotani,
E. R. Mortensen,
D. K. Shumaker, and D. R. Abraczinskas.
1995.
Epidermal growth factor stimulation of the human gastrin promoter requires Sp1.
J. Biol. Chem.
270:6314-6319[Abstract/Free Full Text].
|
| 44.
|
Meyer, D., and C. Birchmeier.
1994.
Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development.
Proc. Natl. Acad. Sci. USA
91:1064-1068[Abstract/Free Full Text].
|
| 45.
|
Murphy, P.,
P. Topilko,
S. Schneider-Maunoury,
T. Seitanidou,
B. V. Evercooren, and P. Charnay.
1996.
The regulation of Krox-20 expression reveals important steps in the control of peripheral glial cell development.
Development
122:2847-2857[Abstract].
|
| 46.
|
Orr-Urtreger, A.,
L. Trakhtenbrot,
R. Ben-Levi,
D. Wen,
G. Rechavi,
P. Lonai, and Y. Yarden.
1993.
Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21.
Proc. Natl. Acad. Sci. USA
90:1867-1871[Abstract/Free Full Text].
|
| 47.
|
Pascal, E., and R. Tjian.
1991.
Different activation domains of Sp1 govern formation of multimers and mediate transcriptional synergism.
Genes Dev.
5:1646-1656[Abstract/Free Full Text].
|
| 48.
|
Peles, E.,
S. S. Bacus,
R. A. Koski,
H. S. Lu,
D. Wen,
S. G. Ogden,
R. Ben-Levy, and Y. Yarden.
1992.
Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells.
Cell
69:205-216[Medline].
|
| 49.
|
Peles, E., and Y. Yarden.
1993.
Inhibitors of protein tyrosine kinases, p. 127-163.
In
M. Sandler, and J. Smith (ed.), Design of enzyme inhibitors as drugs. Oxford University Press, Oxford, United Kingdom.
|
| 50.
|
Perrimon, N., and L. A. Perkins.
1997.
There must be 50 ways to rule the signal: the case of the Drosophila EGF receptor.
Cell
89:13-16[Medline].
|
| 51.
|
Pinkas-Kramarski, R.,
L. Soussan,
H. Waterman,
G. Levkowitz,
I. Alroy,
L. Klapper,
S. Lavi,
R. Seger,
B. Ratzkin,
M. Sela, and Y. Yarden.
1996.
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
EMBO J.
15:2452-2467[Medline].
|
| 52.
|
Robbins, P. D.,
J. M. Horowitz, and R. C. Mulligan.
1990.
Negative regulation of human c-fos expression by the retinoblastoma gene product.
Nature
346:668-671[Medline].
|
| 53.
|
Rohlff, C.,
S. Ahmad,
F. Borellini,
J. Lei, and R. I. Glazer.
1997.
Modulation of transcription factor Sp1 by cAMP-dependent protein kinase.
J. Biol. Chem.
272:21137-21141[Abstract/Free Full Text].
|
| 54.
|
Schaeffer, L.,
N. Duclert,
M. Huchet-Dymanus, and J.-P. Changeux.
1998.
Implication of a multisubunit Ets-related transcription factor in synaptic expression of the nicotinic acetylcholine receptor.
EMBO J.
17:3078-3090[Medline].
|
| 55.
|
Seger, R., and E. G. Krebs.
1995.
The MAP kinase signaling cascade.
FASEB J.
9:726-735[Abstract].
|
| 56.
|
Seidel, H. M.,
H. L. Milocco,
P. Lamb,
J. E. Darnell,
R. B. Stein, and J. Rosen.
1995.
Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity.
Proc. Natl. Acad. Sci. USA
92:3041-3045[Abstract/Free Full Text].
|
| 57.
|
Si, J.,
Z. Luo, and L. Mei.
1996.
Induction of acetylcholine receptor gene expression by ARIA requires activation of mitogen-activated protein kinase.
J. Biol. Chem.
271:19752-19759[Abstract/Free Full Text].
|
| 58.
|
Sliwkowski, M. X.,
G. Schaefer,
R. W. Akita,
J. A. Lofgren,
V. D. Fitzpatrick,
A. Nuijens,
B. M. Fendly,
R. A. Cerione,
R. L. Vandlen, and K. L. Carraway.
1994.
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
J. Biol. Chem.
269:14661-14665[Abstract/Free Full Text].
|
| 59.
|
Sowa, Y.,
T. Orita,
S. Minawikawa,
K. Nakano,
T. Mizuno,
H. Nomura, and T. Sakai.
1997.
Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites.
Biochem. Biophys. Res. Commun.
241:142-150[Medline].
|
| 60.
|
Sunyer, T., and J. P. Merlie.
1993.
Cell type- and differentiation-dependent expression from the mouse acetylcholine receptor -subunit promoter.
J. Neurosci. Res.
36:224-234[Medline].
|
| 61.
|
Topilko, P.,
S. Schneider-Maunoury,
G. Levi,
A. Baron-Van Evercooren,
A. B. Y. Chennoufi,
T. Seitanidou,
C. Babinet, and P. Charnay.
1994.
Krox-20 controls myelination in the peripheral nervous system.
Nature
371:796-799[Medline].
|
| 62.
|
Tzahar, E.,
G. Levkowitz,
D. Karunagaran,
L. Yi,
E. Peles,
S. Lavi,
D. Chang,
N. Liu,
A. Yayon,
D. Wen, and Y. Yarden.
1994.
ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms.
J. Biol. Chem.
269:25226-25233[Abstract/Free Full Text].
|
| 63.
|
Udvadia, A. J.,
D. J. Tempelton, and J. M. Horowitz.
1995.
Functional interactions between the retinoblastoma (Rb) protein and Sp-family members: superactivaton by Rb requires amino acids necessary for growth suppression.
Proc. Natl. Acad. Sci. USA
92:3953-3957[Abstract/Free Full Text].
|
| 64.
|
Verdi, J. M.,
A. K. Groves,
I. Farinas,
K. Jones,
M. A. Marchionni,
L. F. Reichardt, and D. J. Anderson.
1996.
A reciprocal cell-cell interaction mediated by NT-3 and neuregulins controls the early survival and development of sympathetic neuroblasts.
Neuron
16:515-527[Medline].
|
| 65.
|
Wen, D.,
E. Peles,
R. Cupples,
S. V. Suggs,
S. S. Bacus,
Y. Luo,
G. Trail,
S. Hu,
S. M. Silbiger,
R. Ben-Levy,
Y. Luo, and Y. Yarden.
1992.
Neu Differentiation Factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit.
Cell
69:559-572[Medline].
|
| 66.
|
Williams, T., and R. Tjian.
1988.
Analysis of the DNA-binding and activation properties of the human transcription factor AP-2.
Genes Dev.
2:670-682.
|
| 67.
|
Yang, Y.,
E. Spitzer,
D. Meyer,
M. Sachs,
C. Niemann,
G. Hartmann,
K. M. Weidner,
C. Birchmeier, and W. Birchmeier.
1995.
Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland.
J. Cell Biol.
131:215-226[Abstract/Free Full Text].
|
| 68.
|
Zhang, S., and K.-H. Kim.
1997.
Protein kinase CK2 down-regulates glucose-activated expression of the acetyl-CoA carboxylase gene.
Arch. Biochem. Biophys.
338:227-232[Medline].
|
| 69.
|
Zutter, M. M.,
E. E. Ryan, and A. D. Painter.
1997.
Binding of phosphorylated Sp1 protein to tandem Sp1 binding sites regulates 2 integrin gene core promoter activity.
Blood
90:678-689[Abstract/Free Full Text].
|
Molecular and Cellular Biology, March 1999, p. 1961-1972, Vol. 19, No. 3
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Devi, Y. S., Shehu, A., Stocco, C., Halperin, J., Le, J., Seibold, A. M., Lahav, M., Binart, N., Gibori, G.
(2009). Regulation of Transcription Factors and Repression of Sp1 by Prolactin Signaling Through the Short Isoform of Its Cognate Receptor. Endocrinology
150: 3327-3335
[Abstract]
[Full Text]
-
Wu, D. Y. C., Wu, R., Chen, Y., Tarasova, N., Chang, M. M. J.
(2007). PMA Stimulates MUC5B Gene Expression through an Sp1-Based Mechanism in Airway Epithelial Cells. Am. J. Respir. Cell Mol. Bio.
37: 589-597
[Abstract]
[Full Text]
-
Hsu, M.-C., Chang, H.-C., Hung, W.-C.
(2006). HER-2/neu Represses the Metastasis Suppressor RECK via ERK and Sp Transcription Factors to Promote Cell Invasion. J. Biol. Chem.
281: 4718-4725
[Abstract]
[Full Text]
-
Pages, G., Pouyssegur, J.
(2005). Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc Res
65: 564-573
[Abstract]
[Full Text]
-
Zhang, Y., Hamburger, A. W.
(2004). Heregulin Regulates the Ability of the ErbB3-binding Protein Ebp1 to Bind E2F Promoter Elements and Repress E2F-mediated Transcription. J. Biol. Chem.
279: 26126-26133
[Abstract]
[Full Text]
-
Trisciuoglio, D., Iervolino, A., Candiloro, A., Fibbi, G., Fanciulli, M., Zangemeister-Wittke, U., Zupi, G., Del Bufalo, D.
(2004). bcl-2 Induction of Urokinase Plasminogen Activator Receptor Expression in Human Cancer Cells through Sp1 Activation: INVOLVEMENT OF ERK1/ERK2 ACTIVITY. J. Biol. Chem.
279: 6737-6745
[Abstract]
[Full Text]
-
Zhang, J., Wang, S., Wesley, R. A., Danner, R. L.
(2003). Adjacent Sequence Controls the Response Polarity of Nitric Oxide-sensitive Sp Factor Binding Sites. J. Biol. Chem.
278: 29192-29200
[Abstract]
[Full Text]
-
Haisenleder, D. J., Ferris, H. A., Shupnik, M. A.
(2003). The Calcium Component of Gonadotropin-Releasing Hormone-Stimulated Luteinizing Hormone Subunit Gene Transcription Is Mediated by Calcium/Calmodulin-Dependent Protein Kinase Type II. Endocrinology
144: 2409-2416
[Abstract]
[Full Text]
-
Lacazette, E., Le Calvez, S., Gajendran, N., Brenner, H. R.
(2003). A novel pathway for MuSK to induce key genes in neuromuscular synapse formation. JCB
161: 727-736
[Abstract]
[Full Text]
-
Russell, D. L., Doyle, K. M. H., Gonzales-Robayna, I., Pipaon, C., Richards, J. S.
(2003). Egr-1 Induction in Rat Granulosa Cells by Follicle-Stimulating Hormone and Luteinizing Hormone: Combinatorial Regulation By Transcription Factors Cyclic Adenosine 3',5'-Monophosphate Regulatory Element Binding Protein, Serum Response Factor, Sp1, and Early Growth Response Factor-1. Mol. Endocrinol.
17: 520-533
[Abstract]
[Full Text]
-
Schafer, G., Cramer, T., Suske, G., Kemmner, W., Wiedenmann, B., Hocker, M.
(2003). Oxidative Stress Regulates Vascular Endothelial Growth Factor-A Gene Transcription through Sp1- and Sp3-dependent Activation of Two Proximal GC-rich Promoter Elements. J. Biol. Chem.
278: 8190-8198
[Abstract]
[Full Text]
-
Reisinger, K., Kaufmann, R., Gille, J.
(2003). Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription. J. Cell Sci.
116: 225-238
[Abstract]
[Full Text]
-
Yen, L., Benlimame, N., Nie, Z.-R., Xiao, D., Wang, T., Moustafa, A.-E. A., Esumi, H., Milanini, J., Hynes, N. E., Pages, G., Alaoui-Jamali, M. A.
(2002). Differential Regulation of Tumor Angiogenesis by Distinct ErbB Homo- and Heterodimers. Mol. Biol. Cell
13: 4029-4044
[Abstract]
[Full Text]
-
Li, J., Park, S. W., Loh, H. H., Wei, L.-N.
(2002). Induction of the Mouse kappa -Opioid Receptor Gene by Retinoic Acid in P19 Cells. J. Biol. Chem.
277: 39967-39972
[Abstract]
[Full Text]
-
Marinovic, A. C., Zheng, B., Mitch, W. E., Price, S. R.
(2002). Ubiquitin (UbC) Expression in Muscle Cells Is Increased by Glucocorticoids through a Mechanism Involving Sp1 and MEK1. J. Biol. Chem.
277: 16673-16681
[Abstract]
[Full Text]
-
Ross, S., Tienhaara, A., Lee, M.-S., Tsai, L.-H., Gill, G.
(2002). GC Box-binding Transcription Factors Control the Neuronal Specific Transcription of the Cyclin-dependent Kinase 5 Regulator p35. J. Biol. Chem.
277: 4455-4464
[Abstract]
[Full Text]
-
Esparis-Ogando, A., Diaz-Rodriguez, E., Montero, J. C., Yuste, L., Crespo, P., Pandiella, A.
(2002). Erk5 Participates in Neuregulin Signal Transduction and Is Constitutively Active in Breast Cancer Cells Overexpressing ErbB2. Mol. Cell. Biol.
22: 270-285
[Abstract]
[Full Text]
-
Ge, Y., Matherly, L. H., Taub, J. W.
(2001). Transcriptional Regulation of Cell-specific Expression of the Human Cystathionine beta -Synthase Gene by Differential Binding of Sp1/Sp3 to the -1b Promoter. J. Biol. Chem.
276: 43570-43579
[Abstract]
[Full Text]
-
Ragoczy, T., Miller, G.
(2001). Autostimulation of the Epstein-Barr Virus BRLF1 Promoter Is Mediated through Consensus Sp1 and Sp3 Binding Sites. J. Virol.
75: 5240-5251
[Abstract]
[Full Text]
-
Dankort, D., Maslikowski, B., Warner, N., Kanno, N., Kim, H., Wang, Z., Moran, M. F., Oshima, R. G., Cardiff, R. D., Muller, W. J.
(2001). Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer. Mol. Cell. Biol.
21: 1540-1551
[Abstract]
[Full Text]
-
Rafty, L. A., Khachigian, L. M.
(2001). Sp1 phosphorylation regulates inducible expression of platelet-derived growth factor B-chain gene via atypical protein kinase C-{{zeta}}. Nucleic Acids Res
29: 1027-1033
[Abstract]
[Full Text]
-
Xiong, S., Grijalva, R., Zhang, L., Nguyen, N. T., Pisters, P. W., Pollock, R. E., Yu, D.
(2001). Up-Regulation of Vascular Endothelial Growth Factor in Breast Cancer Cells by the Heregulin-{beta}1-activated p38 Signaling Pathway Enhances Endothelial Cell Migration. Cancer Res.
61: 1727-1732
[Abstract]
[Full Text]
-
Martino, A., Holmes, J. H. IV, Lord, J. D., Moon, J. J., Nelson, B. H.
(2001). Stat5 and Sp1 Regulate Transcription of the Cyclin D2 Gene in Response to IL-2. J. Immunol.
166: 1723-1729
[Abstract]
[Full Text]
-
Harris, V. K., Coticchia, C. M., Kagan, B. L., Ahmad, S., Wellstein, A., Riegel, A. T.
(2000). Induction of the Angiogenic Modulator Fibroblast Growth Factor-binding Protein by Epidermal Growth Factor Is Mediated through Both MEK/ERK and p38 Signal Transduction Pathways. J. Biol. Chem.
275: 10802-10811
[Abstract]
[Full Text]
-
YANG, C.-R., WILSON-VAN PATTEN, C., PLANCHON, S. M., WUERZBERGER-DAVIS, S. M., DAVIS, T. W., CUTHILL, S., MIYAMOTO, S., BOOTHMAN, D. A.
(2000). Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation. FASEB J.
14: 379-390
[Abstract]
[Full Text]
-
Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K. III, Siegel, P. M., Hung, M.-C., Yarden, Y., Horowitz, J. M., Muller, W. J., Pestell, R. G.
(2000). Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway. Mol. Cell. Biol.
20: 672-683
[Abstract]
[Full Text]
-
Algarte, M., Kwon, H., Genin, P., Hiscott, J.
(1999). Identification by In Vivo Genomic Footprinting of a Transcriptional Switch Containing NF-kappa B and Sp1 That Regulates the Ikappa Balpha Promoter. Mol. Cell. Biol.
19: 6140-6153
[Abstract]
[Full Text]
-
Larouche, K., Leclerc, S., Salesse, C., Guerin, S. L.
(2000). Expression of the alpha 5 Integrin Subunit Gene Promoter Is Positively Regulated by the Extracellular Matrix Component Fibronectin through the Transcription Factor Sp1 in Corneal Epithelial Cells in Vitro. J. Biol. Chem.
275: 39182-39192
[Abstract]
[Full Text]
-
Talukder, A. H., Jorgensen, H. F., Mandal, M., Mishra, S. K., Vadlamudi, R. K, Clark, B. F. C., Mendelsohn, J., Kumar, R.
(2001). Regulation of Elongation Factor-1alpha Expression by Growth Factors and Anti-receptor Blocking Antibodies. J. Biol. Chem.
276: 5636-5642
[Abstract]
[Full Text]
-
Suarez, E., Bach, D., Cadefau, J., Palacin, M., Zorzano, A., Guma, A.
(2001). A Novel Role of Neuregulin in Skeletal Muscle. NEUREGULIN STIMULATES GLUCOSE UPTAKE, GLUCOSE TRANSPORTER TRANSLOCATION, AND TRANSPORTER EXPRESSION IN MUSCLE CELLS. J. Biol. Chem.
276: 18257-18264
[Abstract]
[Full Text]
-
Price, S. J., Greaves, D. R., Watkins, H.
(2001). Identification of Novel, Functional Genetic Variants in the Human Matrix Metalloproteinase-2 Gene. ROLE OF Sp1 IN ALLELE-SPECIFIC TRANSCRIPTIONAL REGULATION. J. Biol. Chem.
276: 7549-7558
[Abstract]
[Full Text]
-
Laniel, M.-A., Poirier, G. G., Guerin, S. L.
(2001). Nuclear Factor 1 Interferes with Sp1 Binding through a Composite Element on the Rat Poly(ADP-ribose) Polymerase Promoter to Modulate Its Activity in Vitro. J. Biol. Chem.
276: 20766-20773
[Abstract]
[Full Text]